WW upgraded to Buy from Neutral at Goldman Sachs

Goldman Sachs analyst Jason English upgraded WW to Buy from Neutral with a price target of $13, up from $3.80. The company’s subscriber base and earnings power has been shrinking, but a catalyst for a turnaround has emerged with its new obesity drug on-ramp solution, the analyst tells investors in a research note. The firm further states that WW will begin to offer a pharmaceutical based clinical subscription service that it can integrate with its legacy behavioral based weight management offering, and it expects a cohort of consumers to turn to it for help navigating what is poised to be an increasingly complex field of pharmaceutical solutions.